Ember Therapeutics Inc. (EMBT)

[TheInvincibleBull]

$4 up after $1.25

[TheInvincibleBull]

Yep, say if you wanted a nice position of 5k or more it will move it 100%+

[TheInvincibleBull]

$EMBT time to start making new highs

[Dspetry]

VERY tight, and almost impossible to get without chasing on the UT

[TheInvincibleBull]

Yep with Knight($1.15Billion company) it will help selling it

[TheInvincibleBull]

$1.25 up and thin. Grab shares while they are there. Very hard to get

[adijas]

1.25 is up

[adijas]

Migralex sold allready in all CVS-stores. Will expand worldwide with Knighy Therapeutics distribution deal 'Finally, the exclusively licensed territory for Knight has been expanded to include the Caribbean and Romania, in addition to the existing territories of Canada, Israel, Russia, and Sub-Saharan Africa.'
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11489196

[TheInvincibleBull]

Friday at close the ask showed

100 shares at $1.20
2,735 @ $9.45
100 shares @ $13

[TheInvincibleBull]

Good Morning $EMBT

[HMB2010]

Oh my!

[TheInvincibleBull]

Very strong close

[Baseball Bobby]

Didn't notice that EOD action til now. will be watching Monday

[TheInvincibleBull]

$EMBT+Knight=Big $$$$

[TheInvincibleBull]

$EMBT gaining a lot of attention over the weekend. Can't wait for next week

[TheInvincibleBull]

578k listed but only 2,900 shares where on the ask. 100 @ $1.20 2,735@$9.45 and 100@$13 it is so thin it is crazy

[adijas]

578k

[TheFinalCD]

what the freak is the float to move +132% on 6k shares????


$EMBT

[TheInvincibleBull]

What an awesome Friday looking forward to a great next week.

[adijas]

lol

[TheInvincibleBull]

I wanna keep slapping to see if I can hit $9.45 for a little paint :)

[adijas]

1,2!

[TheInvincibleBull]

$9.45 only 1 mm away

[TheInvincibleBull]

Going nuts now

[adijas]

1.1 x 1.2!

[adijas]

1.05 x 1.1

[TheInvincibleBull]

I am with you, $5 minimum so they can uplist

[$hellKing]

Bout time. This is stating to look like its supposed to look

[TheInvincibleBull]

Yep no real ask until $9.45

[adijas]

So thin here with 578k float.

[TheInvincibleBull]

Longs we got this. Let's break $1.10

[TheInvincibleBull]

$1x$1.05

[TheInvincibleBull]

And yes I have high targets because just look at the l2. It's hard as hell to get shares here

[TheInvincibleBull]

$1.10 break and this see's $2's easily then $3's then blue sky's baby

[TheInvincibleBull]

The fact that Knight Therapeutics Inc($1.14billiondollarcompany) is helping $EMBT says big $$$ coming here imo

[$hellKing]

Yup looks really good now

[TheInvincibleBull]

The Bulls getting loaded for next week. I have a feeling more news coming

[adijas]

5k bid at .8. Some people are wanting in badly

[TheInvincibleBull]

That is what I am thinking

[adijas]

They hired a new auditer, so filings will come soon.

[TheInvincibleBull]

Power hour going to be great and next week. Peeps starting to take notice of this hidden sleeper

[adijas]

1.03 x 1.05

[TheInvincibleBull]

Yep and huge bidders coming in

[adijas]

Just got home. Awesome day here. 109% up on just 4k traded.I love this undiscovered low floaters with huge potential!

[TheInvincibleBull]

Awesome, need that to be a sticky as more eyes come here. To get them started

[$hellKing]

EMBT Quick DD Page


CEO quick look at background

CEO and executive chairman Joseph Hernandez is a veteran of companies including Affymetrix, Digene Corp. (now Qiagen), Innovative Biosciences, Prolias Technologies and Signal Genetics.


Here is some of the break down of Migralex

A acquisitions this year was for Migralex

Migralex sold at CVS in stores


Walgreens Online

http://www.walgreens.com/store/c/dr.-mauskop's-migralex-maximum-strength-relief-for-tough-headaches/ID=prod6232285-product


Amazon Online

http://www.amazon.com/Dr-Mauskops-Migralex-20-caplets/dp/B0038PLPLM


drugstore.com

http://www.drugstore.com/dr-mauskops-migralex-maximum-strength-relief-for-tough-headaches/qxp511098


EMBT 450 Patents under their belt

Ember Therapeutics, Inc. is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome. In particular, Ember has acquired over 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and cGMP manufactured material from Stryker Corporation. For more information, please visit www.embertx.com.



Recent News

Ember Therapeutics Completes Reverse Merger and Begins Trading as a Public Company
Mar 21, 2016 Ember Therapeutics Acquires Migralex™ GlobeNewswire

Mar 16, 2016 Ember Therapeutics Enhances Regenerative Medicine Pipeline With Acquisition of ICX-RHY/Vavelta™ from Intercytex GlobeNewswire

EMBT parters Knight Therapeutics Inc. (TSX:GUD) ("Knight"),

Ember Therapeutics to Present at Marcum MicroCap Conference




Worthy notes:
Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.




Officers


Mr. Hernandez, our current Executive Chairman and member of our board of directors, was at Merck and has been involved in the management and founding of several early stage biotechnology companies, including Affymetrix, Digene (now Qiagen), Innovative Biosciences, Inc., Signal Genetics, LLC and Microlin Bio, Inc.


Dean A. Falb, Ph.D.

Scientific Consultant

Dr. Falb is a Consultant at Atlas Ventures. He has broad experience in drug discovery and development in cardiovascular, oncology, inflammation, fibrosis and musculoskeletal disease areas. He has served as the Vice President of Research & Development at Stryker Regenerative Medicine, Vice President of Drug Discovery at Neogenesis (Merck), Senior Vice President of Research & Development at Praecis Pharmaceuticals, and Director of Cardiovascular Diseases at Millennium Pharmaceuticals. Dr. Falb holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University.



Hyun D. Kim, Ph.D.
Vice President of Clinical Development

Dr. Kim is an R&D leader with over 18 years pharmaceutical, biotechnology, and medical device industry and consulting experience leading R&D programs into clinical development and regulatory approvals. He previously led BMP programs at Genetics Institute and Wyeth Pharmaceuticals as well as leadership roles in early stage start-ups. He has served as Director of Product Development at Anika Therapeutics, Senior Director of R&D at Transport Pharmaceuticals, and has served as an R&D, medical affairs, and clinical and regulatory affairs consultant for Biogen Idec, Sunovion, and Teleflex. He has most recently served as the Director of R&D at Olympus Biotech where he led the development of next generation BMP-7 products. Dr. Kim holds a Ph.D. in Medical Science from Brown University, and a Sc.M. and Sc.B. in Biomedical Engineering from Brown University.




Pipeline:





http://www.embertx.com/pipeline.html

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120778797




They have the 14th largest auditor on board.


http://www.accountingweb.com/aa/standards/newly-merged-eisneramper-becomes-14th-largest-accounting-firm-in-nation


They have one of the best transfer agents(usually big boards choose this TA)


American Registrar & Transfer Co.
342 East 900 South Salt Lake City, UT 84111
Phone: [phone]
www.americanregistrar.net

[TheInvincibleBull]

$2 $3 & $3.5 resistances but with this low of a float I don't think they will be that tough imo

[TheInvincibleBull]

The rsi isn't even over 70 yet. So much more room to go!! Need just a little more volume to get us noticed

[TheInvincibleBull]

And btw Knight is a $1.14 Billion dollar company ;)

[TheInvincibleBull]

$EMBT news incase you missed it

June 22, 2016 we entered into a First Amendment to Distribution, License, and Supply Agreement (the “Amendment”) with Knight Therapeutics, Inc. (“Knight”). The Amendment expands the scope of our exclusive distributorship with Knight. Under the Amendment, the field for which Knight shall act as the exclusive distributor of our products has been expanded from the limited fields of osteoarthritis, chronic kidney disease and Alport Syndrome to include all approved human use indications. Further, the licensed products for which Knight will act as our exclusive distributor has been expanded to include all of our current and future products including BMP-7, Migralex TM , and ICX-RHY/Vavelta TM . Finally, the exclusively licensed territory for Knight has been expanded to include the Caribbean and Romania, in addition to the existing territories of Canada, Israel, Russia, and Sub-Saharan Africa.